JP2022501428A5 - - Google Patents
Info
- Publication number
- JP2022501428A5 JP2022501428A5 JP2021539483A JP2021539483A JP2022501428A5 JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5 JP 2021539483 A JP2021539483 A JP 2021539483A JP 2021539483 A JP2021539483 A JP 2021539483A JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- hcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732299P | 2018-09-17 | 2018-09-17 | |
| US201862732334P | 2018-09-17 | 2018-09-17 | |
| US62/732,334 | 2018-09-17 | ||
| US62/732,299 | 2018-09-17 | ||
| PCT/US2019/051529 WO2020061059A1 (en) | 2018-09-17 | 2019-09-17 | Anti-lilrb2 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022501428A JP2022501428A (ja) | 2022-01-06 |
| JP2022501428A5 true JP2022501428A5 (enExample) | 2022-09-29 |
Family
ID=69888746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539483A Pending JP2022501428A (ja) | 2018-09-17 | 2019-09-17 | 抗ｌｉｌｒｂ２抗体およびその使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12157768B2 (enExample) |
| EP (1) | EP3852805A4 (enExample) |
| JP (1) | JP2022501428A (enExample) |
| KR (1) | KR20210108940A (enExample) |
| CN (1) | CN113543804A (enExample) |
| AU (1) | AU2019343131A1 (enExample) |
| CA (1) | CA3111862A1 (enExample) |
| WO (1) | WO2020061059A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113056483B (zh) | 2018-07-09 | 2025-08-01 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
| US20230050449A1 (en) * | 2019-12-20 | 2023-02-16 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| JP2023529557A (ja) | 2020-05-04 | 2023-07-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｎｐｐ１抗体の阻害 |
| JP2023541656A (ja) * | 2020-09-17 | 2023-10-03 | メルク・シャープ・アンド・ドーム・エルエルシー | 癌を治療するための抗ｉｌｔ４抗体またはそれと抗ｐｄ－１抗体との組合せの投与レジメン |
| EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
| KR20230093010A (ko) * | 2020-10-21 | 2023-06-26 | 이뮨-온크 테라퓨틱스, 인코포레이티드 | 신규 항-lilrb2 항체 및 유도체 생성물 |
| IL305794A (en) * | 2021-03-11 | 2023-11-01 | Univ Health Network | LILRB1 and LILRB2 binding molecules and their uses |
| CA3225139A1 (en) * | 2021-07-01 | 2023-01-05 | Albert Einstein College Of Medicine | Compositions and methods for inhibiting the expression of tmigd2 |
| EP4499683A1 (en) * | 2022-03-29 | 2025-02-05 | NGM Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
| WO2023235706A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Combination therapies using ilt-binding agents and pd-1 inhibitors |
| CN115975029A (zh) * | 2022-06-28 | 2023-04-18 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN116333127B (zh) * | 2022-06-28 | 2026-03-24 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN119604531A (zh) * | 2022-07-29 | 2025-03-11 | 盛禾(中国)生物制药有限公司 | 一种抗ilt4的单域抗体及其应用 |
| CN119768432A (zh) * | 2022-08-22 | 2025-04-04 | 德琪(杭州)生物有限公司 | 新颖的抗lilrb2抗体和其用途 |
| TW202413414A (zh) * | 2022-09-08 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｉｌｔ４抗體及其醫藥用途 |
| JP2025532982A (ja) * | 2022-09-28 | 2025-10-03 | スパークス バイオサイエンス リミテッド | 白血球免疫グロブリン様受容体サブファミリーｂメンバー２（ｌｉｌｒｂ２）に結合する抗体とその使用 |
| AU2023410277A1 (en) * | 2022-12-23 | 2025-06-12 | Iomx Therapeutics Ag | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| JP2026504928A (ja) * | 2023-01-20 | 2026-02-10 | ワシントン・ユニバーシティ | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 |
| CN116789826A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗人lilrb2全人源单域抗体及其应用 |
| CN119176874A (zh) * | 2023-06-21 | 2024-12-24 | 康源博创生物科技(北京)有限公司 | 一种能够结合lilrb2的抗体或其抗原结合片段 |
| WO2025128822A1 (en) * | 2023-12-12 | 2025-06-19 | The Methodist Hospital | Lilrb3 modulators and methods of use thereof |
| GB202319149D0 (en) * | 2023-12-14 | 2024-01-31 | Kbio Holdings Ltd | Antibody |
| CN121299117B (zh) * | 2025-12-05 | 2026-03-27 | 中国农业科学院都市农业研究所 | 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2912068B1 (en) | 2012-10-26 | 2019-06-19 | Deutsches Rheuma-Forschungszentrum Berlin | Bi-specific antibodies for cell-lineage-specific tnf-alpha neutralisation |
| ES2673583T3 (es) | 2013-02-28 | 2018-06-22 | National Cancer Center | Anticuerpo contra fibrina insoluble |
| WO2014164519A1 (en) * | 2013-03-12 | 2014-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| CA2948871A1 (en) | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| WO2016111947A2 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA2977544C (en) * | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| DK3541841T3 (da) | 2016-11-18 | 2024-10-21 | Servier Lab | Anti-PD-1-antistoffer og sammensætninger |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
-
2019
- 2019-09-17 AU AU2019343131A patent/AU2019343131A1/en not_active Abandoned
- 2019-09-17 WO PCT/US2019/051529 patent/WO2020061059A1/en not_active Ceased
- 2019-09-17 CA CA3111862A patent/CA3111862A1/en active Pending
- 2019-09-17 JP JP2021539483A patent/JP2022501428A/ja active Pending
- 2019-09-17 CN CN201980075255.5A patent/CN113543804A/zh active Pending
- 2019-09-17 KR KR1020217011459A patent/KR20210108940A/ko not_active Withdrawn
- 2019-09-17 US US17/276,324 patent/US12157768B2/en active Active
- 2019-09-17 EP EP19863793.6A patent/EP3852805A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501428A5 (enExample) | ||
| US12215163B2 (en) | CD25 antibodies | |
| US20240002515A1 (en) | Methods and antibodies for modulation of immunoresponse | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| KR102041832B1 (ko) | 췌장암의 치료 및/또는 예방용 의약 조성물 | |
| KR102052400B1 (ko) | 담낭암의 치료 및/또는 예방용 의약 조성물 | |
| EP3907240A1 (en) | Anti-tnfr2 antibody and use thereof | |
| CN109651507B (zh) | 一种激动型4-1bb单克隆抗体 | |
| US20170327580A1 (en) | Bispecific antibodies against cd3 epsilon and bcma for use in treatment of diseases | |
| KR20190028716A (ko) | Pd-l1-특이적 항체 및 이를 사용하는 방법 | |
| CN114555637A (zh) | 针对ilt2的抗体及其用途 | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| CA3253669A1 (en) | Anti-CD39 antibodies and their use | |
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| SG11202111192TA (en) | Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies | |
| EP3583127B1 (en) | Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof | |
| JP7681879B2 (ja) | Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 | |
| JP6881658B2 (ja) | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| TWI790193B (zh) | 調控免疫反應之方法及抗體 | |
| RU2793165C1 (ru) | Антитело против tnfr2 и его применение | |
| EP4103611B1 (en) | Bispecific antibodies binding hvem and cd9 | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| CN121605130A (zh) | 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体 |